It's what's inside that counts

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3383-3384

  Shewach, Donna S ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; NUCLEOSIDE; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RETENTION; DRUG TOLERABILITY; EDITORIAL; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDICAL RESEARCH; MONOTHERAPY; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; ADENOCARCINOMA; INTRAVENOUS DRUG ADMINISTRATION; NOTE; PANCREAS TUMOR;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; INFUSIONS, INTRAVENOUS; PANCREATIC NEOPLASMS;

EID: 0142058035     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.081     Document Type: Editorial

References (13)

1. Rustum YM, Preisler HD: Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39:42-49, 1979
2. Plunkett W, Iacoboni S, Estey E, et al: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12:20-30, 1985
3. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
4. Tempero M, Plunkett W, Ruiz van Haperen V, et al: Randomized phase II comparison of dose intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003
5. Grunewald R, Abruzzese JL, Tarassoff P, et al: Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991
6. Grunewald R, Kantarjian H, Keating MJ, et al: Pharmacologically directed design of the dose rate and schedule of 2′, 2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
7. Hughes TL, Hahn TM, Reynolds KK, et al: Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry 36:7540-7547, 1997
8. Storniolo AM, Allerheiligen SRB, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24:72-77, 1997
9. Eisbruch A, Shewach DS, Bradford CR, et al: Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 19:792-799, 2001
10. Poplin EA, Corbett T, Flaherty L, et al: Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study. Invest New Drugs 10:165-170, 1992
11. Lund B, Kristjansen PEG, and Hansen HH: Clinical and preclinical activity of 2′, 2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
12. Storniolo AM, Enas NH, Brown CA, et al: An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268, 1999
13. McGinn CJ, Zalupski MA, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001